PAHC
PHIBRO ANIMAL HEALTH CORP
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$39.34
+1.34%Year over year
Reported trailing growth
- Revenue
- +17.1%
- EBITDA
- +59.3%
- EBIT
- +79.6%
- EPS
- +106.7%
- Free cash flow
- -76.4%
- Operating cash flow
- -13.9%
Forward estimates
Based on analyst estimates
- Revenue
- +9.4%
- EBITDA
- +20.2%
- EPS
- +43.7%
Three-year CAGR
- Revenue
- +15.8%
- EBITDA
- +30.6%
- EBIT
- +40.3%
- Net income
- +45.2%
- EPS
- +44.8%
- Free cash flow
- -53.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026